• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Device tax, sluggish sales weigh on Boston Scientific, analysts say

Device tax, sluggish sales weigh on Boston Scientific, analysts say

July 15, 2013 By Arezu Sarvestani

Boston Scientific logo

Analysts at Fitch Ratings affirmed a BBB- rating on Boston Scientific (NYSE:BSX), predicting that cost-control efforts and new product launches won’t be enough to make up for sluggish sales and the effect of the 2.3% medical device tax.

"The healthcare reform-related 2.3% excise tax on U.S. device sales, which was implemented in January 2013, is expected to pressure margins by approximately 1 percentage point," according to Fitch.

Efforts to reduce costs and add higher-margin devices "will help to mitigate this risk," the analysts wrote, but "will not entirely offset the Affordable Care Act’s (ACA’s) 2.3% U.S. sales tax."

The global rating agency predicted "consistently solid" free cash flow for the next 12 months, but warned that relatively flat sales and industry-wide headwinds would keep the Boston Scientific’s margins modest.

Fitch’s Issuer Default Ratings (IDRs) define "an entity’s relative vulnerability to default on financial obligations," indirectly suggesting a company’s likelihood to resort to bankruptcy or other measures. A BBB rating indicates "that expectations of default risk are currently low. The capacity for payment of financial commitments is considered adequate but adverse business or economic conditions are more likely to impair this capacity," according to Fitch.

The rating was based on 5 key "drivers," including a boost from expectations of ongoing operational stability and setbacks from ongoing pricing pressures in cardiac rhythm management and drug-eluting stents as well as Boston Scientific’s "litigation profile."

Fitch analysts added that CRM and interventional cardiology revenues were likely to remain soft in the near future, but that Boston Scientific’s other businesses should generate single-digit growth in the near term.

"Fitch forecasts that BSX will continue to generate consistently solid [free cash flow], owing to fairly durable margins, relatively dependable revenue and manageable [capital expenditure] requirements," according to the report. "The company is expected to maintain adequate liquidity through revolver availability and access to the capital markets."

The analysts predicted that Boston Scientific will suffer sluggish growth during the next 12 months as the medical device giant faces pressures that are weighing down the entire industry, including European austerity measures and pricing pressures from hospitals amid a changing paradigm in healthcare.

BSX shares were down 0.5% to $9.56 as of about 11:15 a.m. today.

Filed Under: News Well, Wall Street Beat Tagged With: Boston Scientific

More recent news

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Johnson & Johnson launches daily disposable multifocal toric contact lens
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy